Locations:

Analysis Reveals Considerable Off-Label Use of Direct Oral Anticoagulants After Heart Valve Replacement

Investigators urge caution until more data accrue

21-HVI-2062967_blood-clot_650x450

Use of direct oral anticoagulants (DOACs) following surgical heart valve replacement is not insignificant in the United States even though satisfactory safety data on DOACs in this setting are lacking. So finds a retrospective national cohort study published by Cleveland Clinic researchers in JAMA Network Open [Epub 8 March 2021].

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“DOAC use is contraindicated in patients with mechanical heart valves, and it remains off-label in those with bioprosthetic heart valves,” says the study’s lead and corresponding author, Ankur Kalra, MD, Medical Director of Clinical Research for Regional Cardiovascular Medicine at Cleveland Clinic. “Despite this lack of FDA labeling and an absence of guideline support, our study found DOAC use among more than 1% of patients with mechanical valves and steadily increasing use among patients with bioprosthetic valves, at about 7% by study’s end.”

He and his co-investigators extracted data from the Society of Thoracic Surgeons Adult Cardiac Surgery Database on all patients who underwent surgical aortic valve replacement (AVR) or mitral valve replacement (MVR) with either mechanical or bioprosthetic heart valves from July 2014 through June 2017. They set out to determine the prevalence of DOAC use at hospital discharge among these patients and compare pre- and postoperative profiles between patients discharged on DOACs and those discharged on warfarin.

Findings in mechanical valve recipients

  • Among 18,142 patients receiving a mechanical valve for AVR, 1.1% were taking a DOAC at discharge.
  • Among 13,942 patients receiving a mechanical valve for MVR, 1.04% were taking a DOAC at discharge.
  • In both the AVR and MVR groups, rates of DOAC use held consistent throughout the study period and the DOAC used was a factor Xa inhibitor in about two-thirds of cases and a thrombin inhibitor in about one-third of cases.

Findings in bioprosthetic valve recipients

  • Among 116,203 patients receiving a bioprosthetic valve for AVR, 4.66% were taking a DOAC at discharge. The rate of DOAC use increased steadily across the study period, from 3.30% in 2014 to 6.64% in 2017 (P = 0.02 for trend).
  • Among 39,243 patients receiving a bioprosthetic valve for MVR, 5.89% were taking a DOAC at discharge. The rate of DOAC use increased steadily across the study period, from 3.94% in 2014 to 7.72% in 2017 (P = 0.03 for trend).
  • In both the AVR and MVR groups, the DOAC used was a factor Xa inhibitor in the large majority of cases (82% and 87%, respectively), with thrombin inhibitors used in the remaining cases.

Advertisement

Profiles of mechanical valve recipients by anticoagulant

Among recipients of mechanical valves across the entire cohort, those discharged on a DOAC alone (no warfarin) were older than those discharged on warfarin alone (no DOAC) (mean of 60.8 vs. 53 years; P < 0.001) and had a significantly lower mean INR. They were also significantly more likely than warfarin recipients to have preoperative hypertension, dyslipidemia, peripheral artery disease and heparin-induced thrombocytopenia (HIT) antibody. Preoperative use of factor Xa inhibitors was also significantly higher among those discharged on a DOAC than those discharged on warfarin. Additionally, postoperative (but pre-discharge) events were significantly more frequent in those discharged on DOACs than those discharged on warfarin, including atrial fibrillation/flutter, reoperation for bleeding and venous thromboembolism.

Profiles of bioprosthetic valve recipients by anticoagulant

Among recipients of bioprosthetic valves across the cohort, those discharged on a DOAC alone (no warfarin) were significantly more likely to have preoperative arrhythmias and HIT antibody than those discharged on warfarin alone (no DOAC), but they were significantly less likely to be on dialysis. Preoperative use of DOACs was higher in the DOAC group. Rates of postoperative (but pre-discharge) events were split between the groups, with renal failure and reoperation for bleeding higher among those discharged on warfarin but atrial fibrillation/flutter and venous thromboembolism higher in those discharged on DOACs.

Caution advised around off-label DOAC use

The researchers note that while their analysis is limited by a lack of follow-up data to compare outcomes according to the type of anticoagulant received, it calls for circumspection around the off-label use of DOACs in patients with newly implanted prosthetic valves.

Advertisement

“These findings call for a pause and caution from clinicians taking care of these patients,” says co-investigator Samir Kapadia, MD, Chair of Cardiovascular Medicine at Cleveland Clinic. “We ought to wait until more data accrue regarding the efficacy and safety of DOACs in these patient subsets.”

Advertisement

Related Articles

color echocardiogram with a podcast icon overlay in the middle

Management of Complex Aortic Valve Endocarditis (Podcast)

Medical and surgical perspectives on the condition’s many high-risk scenarios

axial image of the human chest showing the heart and other organs

How Imaging Can Guide Smarter Aortic Valve and Root Decisions

New review proposes a multimodality framework for matching patients to procedures

color cardiac echo next to model of a bulging aorta

Distinctive CME on Valve Imaging and Connective Tissue Disorders on Tap for March 2027

In-depth live symposia in Florida and Cleveland feature interdisciplinary experts from around the nation

yellow and red illustration of blood cells moving through a blood vessel

First-in-Human Data Show One siRNA Can Lower Both LDL-C and Triglycerides

Early results for ARO-DIMER-PA point to a more streamlined way to treat mixed hyperlipidemia

blood vessel on top of a DNA double helix

CRISPR-Cas9 Gene Editing Therapy Safely Slashes Severely Elevated Triglycerides in Early Trial

Findings support further studies of potential one-time treatment strategy

two side-by-side medical illustrations with red trend line overlays

Lipoprotein(a) Reduction With Pelacarsen Has No Impact on Cardiac Events, Lp(a)HORIZON Finds

But unexpected results are ‘not the end of the story’ for Lp(a) lowering, investigators say

stylized heart and lungs with text overlay

Outcome Updates in Adult Cardiac Surgery, Ischemic Heart Disease and Vascular Disease

A scannable snapshot of recent volumes and results

illustration of aortic arch after stent graft repair

Evolving Strategies in Aortic Arch Repair (Podcast)

Earlier detection is reshaping timing and safety of these increasingly common surgeries

Ad